EGFR and non-small cell lung carcinoma: According to the European Association of Neuro-Oncology-European Society for Medical Oncology (EANO-ESMO) and the American Society for Clinical Oncology-Society for Neuro-Oncology-American Society for Radiation Oncology (ASCO-SNO-ASTRO) guidelines, EGFRm NSCLC patients with asymptomatic or oligo symptomatic BMs were recommended to use EGFR-TKIs without radiotherapy (Rhun et al. 2021; Vogelbaum et al. 2022).